Caerus US 1 Inc.

Caerus US 1 Inc., a for-profit software and data-services company headquartered in New York, sells federal agencies subscriptions to pharmaceutical information databases, clinical trial intelligence platforms, and drug development market intelligence tools as a prime contractor (81% of recent awards) and, more recently, as a subcontractor on health IT support programs. The vendor operates without SBA set-aside designations and competes full-and-open across all customer agencies; the source identifies the company as foreign-owned.

Caerus US 1 Inc. operates as Citeline, a specialized provider of curated pharmaceutical and clinical data. Its capability portfolio centers on three concrete product lines: TrialTrove, a global clinical trials database with biomarker and genomic data fields that supports oncology research; Citeline's Pink Sheet and Generics Bulletin, proprietary pharmaceutical market intelligence and drug development publications; and Biomedtracker, a pharmaceutical IP and deal-intelligence database covering chemicals, royalties, and patent filings. Representative prime awards include a $233 thousand renewal license agreement to the Office of the Assistant Secretary for Preparedness and Response for four Informa Pharma publications (Pharmaprojects, Pink Sheet Online, Trial Predict, TrialTrove); a $247.5 thousand sole-source definitive contract with the Federal Trade Commission's Office of Policy Planning for access to Managed Markets Insight & Technology's Formulary Analytics; and a $119.3 thousand subscription renewal with the Federal Trade Commission (awarded September 2026). More recently, Caerus US 1 Inc. secured a $87 thousand purchase order from the Assistant Secretary for Financial Resources (September 2026) for TrialTrove+ license renewal supporting the National Cancer Institute's Cancer Data Science Laboratory, and a $59.9 thousand multi-user license subscription from the National Cancer Institute (February 2026) covering two concurrent user seats with daily updates and analyst consultation services.

Caerus US 1 Inc.'s customer concentration is heavily weighted toward HHS health research components. The top five funding agencies account for 81% of recent awards by count. The Federal Trade Commission leads by potential value ($441 thousand across three awards), while the National Cancer Institute is the highest-volume customer (four awards, $136 thousand combined potential value). The Office of the Assistant Secretary for Preparedness and Response ($233 thousand) and the National Center for Advancing Translational Sciences ($52 thousand) round out the active set within HHS. When ranked by potential value alone, the FDA ranks first ($596 thousand from a single award), displacing the National Cancer Institute by volume. The vendor places task orders on Alliant II (two orders) and the Multiple Award Schedule (one order).

Activity has grown modestly — one award in 2022 to five in 2024 — though 2025 and 2026 show flatter trajectories with two and four awards respectively. Three awards (combined potential value $281 thousand) reach ultimate completion in the next twenty-four months and face recompete exposure. In its subcontractor role, Caerus US 1 Inc. delivers data analytics and program support to Research Triangle Institute on a Medicare Prescription Drug Inflation Reduction Act implementation sub-award (March 2026), and provides enterprise IT procurement support to Leidos on two consecutive-year BARDA health IT contracts (October 2024, September 2025). Across NAICS framing, the vendor's work spans Software Publishers (four awards), Computer Systems Design Services (three awards), and Periodical Publishers (two awards), reflecting its dual posture as both software-licensing and information-publishing provider.